Disinfection stations provider SafePass announced on Tuesday that it has launched the SafePass IDS (Intelligent Disinfectant Station) solution, a breakthrough system that works as the first line of defence against harmful pathogens.
The company said its SafePass IDS station presents individuals with a temperature check and mask detection system. Its low dose ultraviolet C (UV-C) light sanitizing feature provides minimal light therapy with a wavelength between 200 and 400 nanometers. This process has been routinely used to kill bacteria and viruses and is reportedly harmless to the human body. The disinfectant solution contains an active ingredient of hydrogen peroxide H202 (200 ppm and vaporized) which is recommended by the FDA to kill viruses such as coronavirus. The system also includes a mounted touchless hand sanitizer dispenser.
SafePass added that its system can protect the general public in large gatherings such as movie theatres, restaurants, schools and universities can provide a level of confidence to consumers. Food processing plants are also using the SafePass system for a solution to monitor employees and staff to help insure a COVID-free work environment.
An emerging company specializing in equipment developed to mitigate the transmission of COVID-19 and SARS-CoV-2, SafePass has sold over 150 of its signature disinfection stations worldwide. It has three distribution centres in the US (MD, TX and AR).
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT